Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Perfect NEWS !

<< Previous

Bullboard Posts

Next >>

Comment by whisky11on Jul 27, 2021 4:28pm

123 Views

Post# 33611680

RE:RE:RE:Perfect NEWS !

Kaiser]

LOL! Moe pumping this dumpster fire?! Bahahhahha This guys track record is laughable at best. This is the same clown who pumped Sona and you know where that is.

Like I said this was a gift to shorts post rs!
Back down to reality. Poor no more money moe.

whisky11: so what's wrong with R-107
No information? Do you see short activity today or yesterday? You sound like idiot